Oncolytics Biotech Inc

Oncolytics Biotech® Announces Type C FDA Meeting to Discuss Single-arm Registrational Pathway for Pelareorep in Anal Cancer

Oncolytics Biotech® Completes Domicile Change to the United States

Oncolytics Biotech® to Present New Mechanistic and Translational Data Supporting Pelareorep as an Immune-Priming Backbone at AACR 2026

Oncolytics Biotech® Launches Randomized Colorectal Cancer Study

Oncolytics Biotech® to Prioritize Registration-Focused Programs in Anal and Colorectal Cancer